Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-09-06-Speech-2-368"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20050906.36.2-368"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Mr President, the regulation on the safety of medicinal products for paediatric use is a necessary and sensible alternative that puts an end to a long period of uncertainty surrounding medicinal products in the paediatric sector. The Commission’s proposal was well-balanced and was based on impact assessments. A six-month extension of patent protection as an incentive for pharmaceutical manufacturers is reasonable. This period is based on the results of the impact study and is a clear, fair basis for calculation for all manufacturers.
I am pleased that a majority in Parliament supports this fixed period. Variable patent protection is impracticable and entails a considerable administrative burden. In addition, the duration of a patent must never be dependent on a product’s sales figures. The international competitive situation of the research-oriented pharmaceutical industry demands that we take a look at Europe’s attractiveness as a research destination. This is another reason why I see no material arguments in favour of the reduction in the fixed six-month period that is still under discussion."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples